Cargando…

Correction: The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

Detalles Bibliográficos
Autores principales:	Adamo, Barbara, Ricciardi, Giuseppina Rosaria Rita, Ieni, Antonio, Franchina, Tindara, Fazzari, Carmine, Sanò, Maria Vita, Angelico, Giuseppe, Caruso, Michele, Tuccari, Giovanni, Adamo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368234/ https://www.ncbi.nlm.nih.gov/pubmed/30783520 http://dx.doi.org/10.18632/oncotarget.26650

Ejemplares similares

The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
por: Adamo, Barbara, et al.
Publicado: (2017)

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni, Antonio, et al.
Publicado: (2016)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
por: Russo, Alessandro, et al.
Publicado: (2019)

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2018)

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
por: Franchina, Mariausilia, et al.
Publicado: (2023)

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
por: Russo, Alessandro, et al.
Publicado: (2018)

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma
por: Viana, Aline de Oliveira Ribeiro, et al.
Publicado: (2020)

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study
por: Pergolizzi, Stefano, et al.
Publicado: (2011)

P39.09 Social Media Support of Lung Cancer Patient Associations During the Lockdown Restrictions in Italy: A Breath of Life During the COVID-19 Pandemic.
por: Franchina, V., et al.
Publicado: (2021)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023)

Evaluation of Ki67, p16 and CK17 Markers in Differentiating Cervical Intraepithelial Neoplasia and Benign Lesions
por: Sari Aslani, Fatemeh, et al.
Publicado: (2013)

Human Epidermal Growth Factor Receptor 2 Status in Gastric Carcinomas with Distinctive Prevalent Cribriform Component
por: Ieni, Antonio, et al.
Publicado: (2018)

Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
por: Adamo, Vincenzo, et al.
Publicado: (2012)

Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
por: Kashiwagi, Shinichiro, et al.
Publicado: (2011)

Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China
por: Song, Qingbin, et al.
Publicado: (2011)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence
por: Ziaran, Stanislav, et al.
Publicado: (2020)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma
por: Huang, Lihua, et al.
Publicado: (2018)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

The nucleolar protein NIFK promotes cancer progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell proliferation
por: Lin, Tsung-Chieh, et al.
Publicado: (2016)

Partial Oxygen Pressure Affects the Expression of Prognostic Biomarkers HIF-1 Alpha, Ki67, and CK20 in the Microenvironment of Colorectal Cancer Tissue
por: Zhang, Lirong, et al.
Publicado: (2016)

Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67
por: Asgari, Mojgan, et al.
Publicado: (2016)

Role of Maspin, CK17 and Ki-67 Immunophenotyping in Diagnosing of Pancreatic Ductal Adenocarcinoma in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology
por: Mamdouh, Mona M, et al.
Publicado: (2021)

Expression of matrix metalloproteinase 2 (MMP-2), E-cadherin and Ki-67 in metastatic and non-metastatic canine mammary carcinomas
por: Nowak, Marcin, et al.
Publicado: (2016)

Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report
por: Angelico, Giuseppe, et al.
Publicado: (2018)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
por: Ieni, Antonio, et al.
Publicado: (2021)

Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade
por: Burger, M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_tksh7tmqv2u1u7v5633ei5fuli